Terms: = Prostate cancer AND CLTC, CLTCL2, 1213, ENSG00000141367, Q00610 AND Treatment
10 results:
1. Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study.
Grande E; Arranz JÁ; De Santis M; Bamias A; Kikuchi E; Del Muro XG; Park SH; De Giorgi U; Alekseev B; Mencinger M; Izumi K; Schutz FA; Puente J; Li JR; O'Donnell PH; Kalebasty AR; Ye D; Mariathasan S; Bene-Tchaleu F; Bernhard S; Lee C; Davis ID; Galsky MD
Lancet Oncol; 2024 Jan; 25(1):29-45. PubMed ID: 38101433
[TBL] [Abstract] [Full Text] [Related]
2. Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study.
Bamias A; Davis ID; Galsky MD; Arranz JÁ; Kikuchi E; Grande E; Del Muro XG; Park SH; De Giorgi U; Alekseev B; Mencinger M; Izumi K; Schutz FA; Puente J; Li JR; Panni S; Gumus M; Özgüroğlu M; Mariathasan S; Poloz Y; Bene-Tchaleu F; Lee C; Bernhard S; De Santis M
Lancet Oncol; 2024 Jan; 25(1):46-61. PubMed ID: 38101431
[TBL] [Abstract] [Full Text] [Related]
3. A Systematic Review of the Evidence for the Decipher Genomic Classifier in prostate cancer.
Jairath NK; Dal Pra A; Vince R; Dess RT; Jackson WC; Tosoian JJ; McBride SM; Zhao SG; Berlin A; Mahal BA; Kishan AU; Den RB; Freedland SJ; Salami SS; Kaffenberger SD; Pollack A; Tran P; Mehra R; Morgan TM; Weiner AB; Mohamad O; Carroll PR; Cooperberg MR; Karnes RJ; Nguyen PL; Michalski JM; Tward JD; Feng FY; Schaeffer EM; Spratt DE
Eur Urol; 2021 Mar; 79(3):374-383. PubMed ID: 33293078
[TBL] [Abstract] [Full Text] [Related]
4. Detection of Individual prostate cancer Foci via Multiparametric Magnetic Resonance Imaging.
Johnson DC; Raman SS; Mirak SA; Kwan L; Bajgiran AM; Hsu W; Maehara CK; Ahuja P; Faiena I; Pooli A; Salmasi A; Sisk A; Felker ER; Lu DSK; Reiter RE
Eur Urol; 2019 May; 75(5):712-720. PubMed ID: 30509763
[TBL] [Abstract] [Full Text] [Related]
5. treatment in the STAMPEDE era for castrate resistant prostate cancer in the UK: ongoing challenges and underappreciated clinical problems.
Greasley RU; Turner R; Collins K; Brown J; Bourke L; Rosario DJ
BMC Cancer; 2018 Jun; 18(1):667. PubMed ID: 29914436
[TBL] [Abstract] [Full Text] [Related]
6. The
Scarpa L; Buxbaum S; Kendler D; Fink K; Bektic J; Gruber L; Decristoforo C; Uprimny C; Lukas P; Horninger W; Virgolini I
Eur J Nucl Med Mol Imaging; 2017 May; 44(5):788-800. PubMed ID: 28083690
[TBL] [Abstract] [Full Text] [Related]
7. Morbidity of focal therapy in the treatment of localized prostate cancer.
Barret E; Ahallal Y; Sanchez-Salas R; Galiano M; Cosset JM; Validire P; Macek P; Durand M; Prapotnich D; Rozet F; Cathelineau X
Eur Urol; 2013 Apr; 63(4):618-22. PubMed ID: 23265382
[TBL] [Abstract] [Full Text] [Related]
8. Low prostate-specific antigen and no Gleason score upgrade despite more extensive cancer during active surveillance predicts insignificant prostate cancer at radical prostatectomy.
Han JS; Toll AD; Amin A; Carter HB; Landis P; Lee S; Epstein JI
Urology; 2012 Oct; 80(4):883-8. PubMed ID: 22921697
[TBL] [Abstract] [Full Text] [Related]
9. The definition of biochemical failure in patients treated with definitive radiotherapy.
Kattan MW; Fearn PA; Leibel S; Potters L
Int J Radiat Oncol Biol Phys; 2000 Dec; 48(5):1469-74. PubMed ID: 11121650
[TBL] [Abstract] [Full Text] [Related]
10. Clinical utility of cellular DNA measurements in prostate carcinoma. Consensus Conference on Diagnosis and Prognostic Parameters in Localized prostate cancer. Stockholm, Sweden, May 12-13, 1993.
Schröder F; Tribukait B; Böcking A; DeVere White R; Koss L; Lieber M; Stenkvist B; Zetterberg A
Scand J Urol Nephrol Suppl; 1994; 162():51-63; discussion 15-27. PubMed ID: 7529429
[TBL] [Abstract] [Full Text] [Related]
